While randomization is required by regulatory bodies, it is up to the sponsor on how to conduct it.
Jennifer Ross
Advertisement
Director of Biostatistics, Almac Clinical Technologies
Articles by Jennifer Ross
It is unrealistic to include infinite adaptations in an IRT system, thus identifying the optimal level of adaptations requires examination of the study’s characteristics and planning phase considerations.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Imfinzi Regimen Demonstrates 22% Survival Benefit in Early Gastric and GEJ Cancer
2
Thermo Fisher, Lundbeck Announce New OpenAI Partnerships Advancing AI in Drug Development
3
Reducing Site Burden Through Better Technology Integration in Clinical Trials
4
ACT Brief: AI Partnerships, Data-Driven Site Activation, and FDA Approval for Omvoh’s Single-Injection Regimen
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
